Promoters for Glaucoma Gene Therapy
About the Research Project
Program
Award Type
Standard
Award Amount
$49,986
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999005
Summary
Gene therapy may prove to be an ideal form of treatment for diseases with genetic causes because a normal version of a gene could be introduced into cells to restore functions that have been disrupted due to the genetic mutation. If gene therapy is to be used one day for treating forms of glaucoma, two requirements must be met. First, one needs an efficient means, or vector, for placing genes in eye tissues. Second, genetic elements called promoters are required that will allow the therapeutic gene to be specifically turned on in the appropriate cell type (e.g. TM cells). Dr. Brandt has already attained the first goal and is now focused on identifying TM cell-specific promoters.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute